ReviewJournal of neuro-oncology2006
Mechanisms of angiogenesis in gliomas.
Review in Journal of neuro-oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Pooled it
- The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2014Guideline
- Safety of bevacizumab in patients with malignant gliomas: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Pooled it
- Pooled it
- Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma.Frontiers in immunology · 2020Trial
- Trial
- A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).Journal of neuro-oncology · 2014Trial
- Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Salvage therapy with single agent bevacizumab for recurrent glioblastoma.Journal of neuro-oncology · 2010Trial
- Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.Journal of neuro-oncology · 2009Trial
- Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.Neuro-oncology · 2008Trial
- Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Neuro-oncology · 2007Trial
- Driver gene-specific prevalence and incidence of brain metastases in non-small cell lung cancer: a meta-analysis encompassing all disease stages.Discover oncology · 2025Article
- Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.Experimental hematology & oncology · 2024Review
- Implications of Cellular Immaturity in Necrosis and Microvascularization in Glioblastomas IDH-Wild-Type.Clinics and practice · 2022Article
- Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study.Future science OA · 2022Article
- Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies.Exploration of targeted anti-tumor therapy · 2022Review
- Fibroblast Growth Factor Signalling in the Diseased Nervous System.Molecular neurobiology · 2021Review
- Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells.Oncology letters · 2021Article
- A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.Neuro-oncology · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most frequent primary tumors of the central nervous system in adults. Glioblastoma multiforme, the most aggressive form of astrocytic tumors, displays a rapid progression that is accompanied by particular poor prognosis of patients. Intense angiogenesis is a distinguishing pathologic characteristic of these tumors and in fact, glioblastomas are of the most highly vascularized malignant tumors. For this reason, research and therapy strategies have focused on understanding the mechanisms leading to the origin of tumor angiogenic blood vessels in order to develop new approaches that effectively block angiogenesis and cause tumor regression. We discuss here some important features of glioma angiogenesis and we present molecules and factors and their possible functions and interactions that play a role in neovascularization. In spite of the great progress that molecular biology has achieved on investigating tumor angiogenesis, many aspects remain obscure and the complexity of the angiogenic process stands for an obstacle in identifying the exact and complete molecular pathways orchestrating new blood vessels formation, which are necessary for the survival and expansion of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.